| About: | Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company provides intermediates; high-purity multi-cyclic and long-chain peptides; specialty and biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, orally disintegrating films, transdermal patches, and lyophilized injectables. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India. |